Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.11.5477 on December 3 2007

Journal of Clinical Oncology, Vol 26, No 2 (January 10), 2008: pp. 211-217
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rezvani, A. R.
Right arrow Articles by Maloney, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rezvani, A. R.
Right arrow Articles by Maloney, D. G.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma

Andrew R. Rezvani, Barry Storer, Michael Maris, Mohamed L. Sorror, Edward Agura, Richard T. Maziarz, James C. Wade, Thomas Chauncey, Stephen J. Forman, Thoralf Lange, Judith Shizuru, Amelia Langston, Michael A. Pulsipher, Brenda M. Sandmaier, Rainer Storb, David G. Maloney

From the Fred Hutchinson Cancer Research Center; University of Washington; Veterans Affairs Puget Sound Health System, Seattle, WA; Rocky Mountain Cancer Center, Denver, CO; Baylor University, Dallas, TX; Oregon Health and Science University, Portland, OR; Medical College of Wisconsin, Milwaukee, WI; City of Hope National Medical Center, Duarte; Stanford University, Stanford, CA; Emory University, Atlanta, GA; University of Utah, Salt Lake City, UT; and University of Leipzig, Leipzig, Germany

Corresponding author: David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1-100, Seattle, WA 98109; e-mail: dmaloney{at}fhcrc.org

Purpose: Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting.

Patients and Methods: Sixty-two patients with indolent or transformed NHL were treated with allogeneic HCT from related (n = 34) or unrelated (n = 28) donors after conditioning with 2 Gy of total-body irradiation with or without fludarabine. Nine unrelated donors were mismatched for ≥ one HLA antigen. Sixteen patients had histologic transformation before HCT. Twenty patients (32%) had progressive disease after previous high-dose therapy with autologous HCT. Median age was 54 years, and patients had received a median of six lines of treatment before HCT. Median follow-up time after HCT was 36.6 months.

Results: At 3 years, the estimated overall survival (OS) and progression-free survival (PFS) rates were 52% and 43%, respectively, for patients with indolent disease, and 18% and 21%, respectively, for patients with transformed disease. Patients with indolent disease and related donors (n = 26) had 3-year estimated OS and PFS rates of 67% and 54%, respectively. The incidences of grade 2 to 4 acute graft-versus-host disease (GVHD), grade 3 and 4 acute GVHD, and extensive chronic GVHD were 63%, 18%, and 47%, respectively. Among survivors, the median Karnofsky performance status at last follow-up was 85%.

Conclusion: Nonmyeloablative allogeneic HCT can produce durable disease-free survival in patients with relapsed or refractory indolent NHL, even in this relatively elderly and heavily pretreated cohort. Outcomes were particularly good in patients with untransformed disease and related donors, whereas patients with transformed disease did poorly. Long-term survivors reported good overall functional status.

published online ahead of print at www.jco.org on December 3, 2007.

Supported by Grants No. CA78902, CA18029, CA15704, and K99-HL088021 from the National Institutes of Health, Bethesda, MD.

Presented in part as a poster at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
JWatch Oncology and HematologyHome page
Allogeneic Stem-Cell Transplantation for Indolent Lymphoma
Journal Watch Oncology and Hematology, March 4, 2008; 2008(304): 2 - 2.
[Full Text]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online